MedTrace Logo

Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

NCT00725842 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2015-09-21

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine the relapse rate in the French patient population with chronic hepatitis C (CHC) previously treated with PegInterferon Alfa-2b (Peg-IFN alfa-2b) plus Ribavirin according to standard clinical practice. Treatment was to be completed prior to the enrollment in the current study. The study will also aim to identify factors that are predictive of relapse. Relapse rate is defined as the percentage of patients with negative viral load at end of treatment who again have positive viral load at 6 months after the end of treatment.

Conditions

  • Hepatitis C
  • Hepatitis C, Chronic

Interventions

BIOLOGICAL

Peg-IFN alfa-2b

Peg-IFN alfa-2b administered in accordance with approved labeling

DRUG

Ribavirin

Ribavirin administered in accordance with approved labeling

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725842 on ClinicalTrials.gov